Loading...
Docoh

Eric D Larson

Filed: 31 May 19, 4:21pm
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Larson Eric D

(Last)(First)(Middle)
C/O PROTEOSTASIS THERAPEUTICS, INC.
80 GUEST STREET, SUITE 500

(Street)
BOSTONMA02135

(City)(State)(Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
05/31/2019
3. Issuer Name and Ticker or Trading Symbol
PROTEOSTASIS THERAPEUTICS, INC. [ PTI ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)2. Amount of Securities Beneficially Owned (Instr. 4)3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)4. Conversion or Exercise Price of Derivative Security5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)(1)08/08/2028Common Stock17,0002.74D
Stock Option (Right to Buy)(2)03/01/2029Common Stock9,6004.3D
Explanation of Responses:
1. These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on August 8, 2019, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on August 8, 2022, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities.
2. These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on February 5, 2020, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on February 5, 2023, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities.
Remarks:
Principal Financial Officer and Principal Accounting Officer
/s/ Janet Smart, Attorney-in-Fact05/31/2019
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.